RegenLab, a pioneering biotechnology company specializing in the research, and manufacturing of patented cell and tissue engineering medical devices, has been honoured with the “Innovation Champion Award” by the European Investment Bank (EIB) at the Adventure Debt Summit held at the European Convention Center in Luxembourg.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716529298/en/

Antoine Turzi receives EU-EIB Innovation Champion Award. Antoine Turzi, Founder and President of RegenLab, pictured between two officials of the European Investment Bank. (Photo: Business Wire)

This prestigious award recognizes RegenLab France’s commitment to “reshoring” by establishing a state-of-the-art biotechnology factory in Paris-Saclay and its innovative work on the “REGENMATRIX PRP-HA”. This next-generation product combines Platelet-Rich Plasma (PRP) with cross-linked Hyaluronic Acid (HA) in a single tube, designed specifically to address the needs of patients with advanced grade III-IV knee osteoarthritis. Currently, a clinical study is underway in 16 university hospitals across France to demonstrate the effectiveness and safety of this groundbreaking treatment.

“We are honored and delighted to receive this award from the European Investment Bank,” said Mr. Antoine Turzi, Founder & President of RegenLab group. “This recognition celebrates the successful completion of our French factory and our ongoing R&D efforts. Our goal is to innovate in cell therapies that enhance the well-being of patients.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716529298/en/